S-P puts Remicade account up for grabs

Schering-Plough (S-P) is plotting to bring in fresh agency support to promote Remicade in the UK.

Four agencies are believed to have held talks with S-P about 2006 product comms strategy for Remicade, which can be used to treat patients with a number of inflammatory disorders related to the immune system.

The product has previously been promoted in its rheumatoid arthritis indication by Athena Medical PR.

S-P UK comms manager Caroline Rattray, who joined S-P in February from the British Society for Rheumatology (PRWeek, 28 January), said: 'The projects we were working on with Athena came to an end. We are both now looking in new directions.'

She confirmed that agency discussions had taken place for the Remicade account, but declined toconfirm a timescale for an appointment.

Just this month S-P announced that the European Commission had given the thumbs-up for Remicade's use in the treatment of
moderate to severe plaque psoriasis – the most common form of the condition that affects the skin and joints.
The product is already used to treat ailments such as Crohn's disease and rheumatoid arthritis. 

Athena Medical PR's managing director is Cherry Wood.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in